心血管疾患の治療標的としてチオレドキシン相互作用タンパク質 (TXNIP) の探索
Shrutika Date1, Lokesh Kumar Bhatt1
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.
Archiv der Pharmazie
|August 25, 2025
まとめ
チオレドキシン相互作用タンパク質 (TXNIP) は,酸化ストレスと炎症を促進することによって,心血管疾患 (CVD) を誘発する. TXNIPのターゲティングは,CVDの進行を緩和し,患者のアウトカムを改善するための有望な治療戦略を提供します.
科学分野:
- 生物化学
- 分子生物学
- 心臓病科
背景:
- 心血管疾患 (CVD) は世界の主要な死因です.
- 酸化ストレスはCVDの病原性における重要な要因です.
- チオレドキシン相互作用タンパク質 (TXNIP) は,CVDに関与する重要な酸化還元調節剤である.
研究 の 目的:
- 心血管疾患の進行におけるTXNIPの役割を検討する.
- TXNIPがCVDに寄与する分子メカニズムを解明する.
- 心血管疾患の治療対象としてTXNIPを研究する.
主な方法:
- TXNIPのCVDへの関与に関する文献レビュー.
- 酸化ストレスと炎症におけるTXNIPの調節機能の分析
- TXNIPによって影響されるシグナル伝達経路の検査
主要な成果:
- TXNIPは酸化促進剤として作用し,抗酸化機能を妨害し,酸化還元不均衡を引き起こします.
- TXNIPはNLRP3炎症体を活性化し,IL-1βとIL-18の放出と炎症を引き起こします.
- TXNIPは,TRX/ASK1の相互作用を変化させることで,アポトーシスとピロプトーシスを調節する.
- TXNIPは,TXNIP/SIRT1/FOXO1,TXNIP/Redd1,TLR4/NF-κB/TXNIP/NLRP3,およびNRF2/TXNIPを含む主要な信号経路を調節する.
結論:
- TXNIPは,心血管疾患における酸化ストレスと炎症の中心的メディエーターである.
- TXNIPは血管損傷,内皮機能障害,細胞死経路において重要な役割を果たします.
- TXNIPをターゲットにすることで,心臓血管疾患の治療に役立つ可能性がある.
関連する概念動画
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
256
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
256
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15